Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.59 |
| ▸ | CTSS | P25774 | 12/20 | 0.55 |
| ▸ | CTSK | P43235 | 11/20 | 0.55 |
| ▸ | CTSB | P07858 | 4/20 | 0.55 |
| ▸ | CTSL | P07711 | 2/20 | 0.51 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | CCKAR | P32238 | 1/20 | 0.42 |
| ▸ | CCKBR | P32239 | 1/20 | 0.42 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.42 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.42 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.42 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.42 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.42 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6166259 | 0.91 | PTPN1 (0.47) | PTPN1CTSSCTSKCTSBCTSL | |
| SCHEMBL6161556 | 0.89 | CTSS (0.53) | PTPN1CTSSCTSKCTSBCTSL | |
| SCHEMBL6167385 | 0.88 | PTPN1 (0.47) | PTPN1CTSSCTSKCTSBCTSL | |
| SCHEMBL6163926 | 0.87 | USP30 (0.57) | PTPN1CTSSCTSKCTSBCTSL | |
| SCHEMBL6163898 | 0.82 | USP30 (0.47) | PTPN1USP30PSEN1PSEN2APH1B | |
| SCHEMBL2999836 | 0.81 | CTSS (0.69) | PTPN1CTSSCTSKCTSBCTSL | |
| SCHEMBL2999840 | 0.81 | CTSS (0.69) | PTPN1CTSSCTSKCTSBCTSL | |
| SCHEMBL6163562 | 0.81 | USP30 (0.55) | CTSSCTSKCTSBCTSLUSP30 | |
| SCHEMBL6166435 | 0.80 | USP30 (0.59) | USP30 | |
| SCHEMBL6780479 | 0.79 | PTPN1 (0.85) | PTPN1CTSSCTSKCTSBCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1254136-A4 | FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF | LG CHEM INVESTMENT LTD (KR) | 2005-06-01 | — | — | EP | disclosed |
| US-20030065176-A1 | Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof | LG CHEM INVESTMENT LTD. (KR) | 2003-04-03 | — | — | US | disclosed |
| EP-1254136-A1 | FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF | LG Chem Investment, Ltd. (KR) | 2002-11-06 | — | — | EP | disclosed |
| WO-2001055146-A1 | FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF | LG CHEM INVESTMENT LTD. (KR) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065176-A1 | Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof | F2, F12, TFPI | PTPN1 1142/4885CTSS 354/4885CTSK 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.